Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  PCAS    PCA   FR0000053514


News SummaryMost relevantAll newsSector news 

PCAS : Quarterly Financial Information as of March 31st 2012

04/23/2012 | 11:40am US/Eastern

PCAS: Quarterly Financial Information As of March 31st, 2012


Longjumeau, April 23rd,  2012

Business update

(in million of euros) 2012 2011 % change
Sales as of 31 March 42 728 44 053 -3,0%
including Pharmaceutical Synthesis 25 454 27 147 -6,2%
including Specialty Chemicals 17 274 16 906 2,2%

Consolidated revenue for PCAS as of 31 March is down 3% in 2012 compared with 2011.

Pharma Synthesis
Business was affected by the planned reduction in contribution from the new contract between PCAS and Sanofi.  However, it is still more robust than the drop in revenue would suggest, thanks to the manufacture of two products with long production cycles, sales of which will be effective through the second quarter of 2012.

Fine & Speciality Chemicals
Fine & Speciality Chemicals rose slightly by 2.2% in 2012, thanks to the activities of New Technologies whereas, Performance Chemicals and Fragrance-Flavour-Cosmetics are down slightly over the period.

However, these data should not hide the fact that 2012 revenue is still set to be considerably higher than that of 2011.

Confirmation of the Group's development strategy focused on the increase of the percentage of proprietary products and the development of differentiating technologies, coupled with continued rigorous management of all costs, is resulting as from the first quarter of 2012 in significantly higher profitability.

Key operations and events for the quarter

No important events likely to have a significant impact on the company's business or situation occurred during the first quarter of 2012.

Outlook for the current year

As requested by the Board of Directors, the Group's General Management is focusing its action on ensuring sustained improvement in profitability.

Next meeting:
2012 first half sales, on 26 July 2012







Founded in 1962, PCAS is a fine and specialty chemicals group that shares an ambition for excellence with its customers, which primarily include market-leading international groups. PCAS designs and delivers the best industrial solutions for its customers' specific expectations. These various expectations all share a common demand for safety, quality, competitiveness, innovation and sustainability.


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: PCAS via Thomson Reuters ONE

React to this article
Latest news on PCAS
03/27 PCAS : Confirmation of PEA-PME plan eligibility for 2015/2016
03/18 PCAS : MOONLINER® by ENERSENS: ultra-insulating natural-based wall cladding
02/19 PCAS : 2014 Results - Strong Financials and growth prospects lead to return to d..
01/29 PCAS : Expansia has been nominated by UCB Pharma "Vendor of the year 2014"
2014 PCAS : ENERSENS Homeskin project
2014 PCAS : leads the European Union Horizon 2020 Homeskin
2014 PCAS : includes a new Scientific Board in its governance
2014 PCAS : Protéus : At the heart of the Vadébio project
2014 PCAS : joins the new EnterNext© PEA-PME 150 index
2014 PCAS : through its subsidiary Proteus, is contributing to the conversion of wood..
Duration : Period :
PCAS Technical Analysis Chart | PCA | FR0000053514 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes